Reports Q1 revenue $21.624M, consensus $25.07M. “This was an incredibly busy quarter with multiple clinical readouts and trial initiations. We reported positive data from the chronic period of the Phase 2b study of RVT-3101 in ulcerative colitis, in addition to positive data from the ADORING 1 trial evaluating VTAMA in patients as young as 2 years old with moderate-to-severe atopic dermatitis. We also initiated two separate trials, the TAHOE Phase 2 study of RVT-3101 in Crohn’s disease and the Phase 1 study of IMVT-1402 in healthy volunteers. We’re incredibly excited about the progress we’ve made in this quarter alone and look forward to announcing additional clinical results in the upcoming months,” said Matt Gline, CEO of Roivant. “On the commercial side, we saw another three months of continued product revenue growth for the company from VTAMA sales.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ROIV:
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
- ROIV Upcoming Earnings Report: What to Expect?
- Telavant doses first patient in Phase 2 trial of RVT-3101 in CD
- ‘Big Short’ Steve Eisman Says the Stock Market Will Continue Surging as No Recession Signs Emerge — Here Are 2 Stocks That Analysts Like
- Roivant TL1A deal ‘mostly priced in,’ says Jefferies
